Takeda Pharmaceutical Statistics

Total Valuation

Takeda Pharmaceutical has a market cap or net worth of $46.31 billion. The enterprise value is $78.18 billion.

Market Cap	46.31B
Enterprise Value	78.18B

Important Dates

The last earnings date was Wednesday, July 30, 2025, before market open.

Earnings Date	Jul 30, 2025
Ex-Dividend Date	Mar 31, 2025

Share Statistics

Takeda Pharmaceutical has 1.56 billion shares outstanding. The number of shares has increased by 1.18% in one year.

Current Share Class	n/a
Shares Outstanding	1.56B
Shares Change (YoY)	+1.18%
Shares Change (QoQ)	+0.42%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.56B

Valuation Ratios

The trailing PE ratio is 24.98 and the forward PE ratio is 15.08.

PE Ratio	24.98
Forward PE	15.08
PS Ratio	1.49
Forward PS	0.02
PB Ratio	0.97
P/TBV Ratio	n/a
P/FCF Ratio	7.45
P/OCF Ratio	6.06
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.25, with an EV/FCF ratio of 12.58.

EV / Earnings	82.38
EV / Sales	2.52
EV / EBITDA	9.25
EV / EBIT	20.17
EV / FCF	12.58

Financial Position

The company has a current ratio of 1.16, with a Debt / Equity ratio of 0.73.

Current Ratio	1.16
Quick Ratio	0.47
Debt / Equity	0.73
Debt / EBITDA	3.97
Debt / FCF	5.62
Interest Coverage	4.20

Financial Efficiency

Return on equity (ROE) is 1.87% and return on invested capital (ROIC) is 2.71%.

Return on Equity (ROE)	1.87%
Return on Assets (ROA)	2.31%
Return on Invested Capital (ROIC)	2.71%
Return on Capital Employed (ROCE)	4.73%
Revenue Per Employee	$654,374
Profits Per Employee	$19,999
Employee Count	47,455
Asset Turnover	0.30
Inventory Turnover	1.25

Taxes

In the past 12 months, Takeda Pharmaceutical has paid $360.34 million in taxes.

Income Tax	360.34M
Effective Tax Rate	27.49%

Stock Price Statistics

The stock price has increased by +6.64% in the last 52 weeks. The beta is 0.27, so Takeda Pharmaceutical's price volatility has been lower than the market average.

Beta (5Y)	0.27
52-Week Price Change	+6.64%
50-Day Moving Average	14.78
200-Day Moving Average	14.23
Relative Strength Index (RSI)	56.53
Average Volume (20 Days)	5,602,193

Short Selling Information

The latest short interest is 8.22 million, so 0.53% of the outstanding shares have been sold short.

Short Interest	8.22M
Short Previous Month	5.09M
Short % of Shares Out	0.53%
Short % of Float	0.53%
Short Ratio (days to cover)	1.82

Income Statement

In the last 12 months, Takeda Pharmaceutical had revenue of $31.05 billion and earned $949.04 million in profits. Earnings per share was $0.59.

Revenue	31.05B
Gross Profit	20.18B
Operating Income	3.88B
Pretax Income	n/a
Net Income	949.04M
EBITDA	8.45B
EBIT	3.88B
Earnings Per Share (EPS)	$0.59

Full Income Statement

Balance Sheet

The company has $2.43 billion in cash and $34.94 billion in debt, giving a net cash position of -$32.51 billion or -$20.82 per share.

Cash & Cash Equivalents	2.43B
Total Debt	34.94B
Net Cash	-32.51B
Net Cash Per Share	-$20.82
Equity (Book Value)	47.59B
Book Value Per Share	30.46
Working Capital	2.38B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $7.64 billion and capital expenditures -$1.33 billion, giving a free cash flow of $6.21 billion.

Operating Cash Flow	7.64B
Capital Expenditures	-1.33B
Free Cash Flow	6.21B
FCF Per Share	$3.98

Full Cash Flow Statement

Margins

Gross margin is 64.98%, with operating and profit margins of 12.48% and 3.06%.

Gross Margin	64.98%
Operating Margin	12.48%
Pretax Margin	4.22%
Profit Margin	3.06%
EBITDA Margin	27.21%
EBIT Margin	12.48%
FCF Margin	20.01%

Dividends & Yields

This stock pays an annual dividend of $0.54, which amounts to a dividend yield of 3.68%.

Dividend Per Share	$0.54
Dividend Yield	3.68%
Dividend Growth (YoY)	8.72%
Years of Dividend Growth	n/a
Payout Ratio	91.86%
Buyback Yield	-1.18%
Shareholder Yield	2.50%
Earnings Yield	2.05%
FCF Yield	13.41%

Dividend Details

Analyst Forecast

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Takeda Pharmaceutical has an Altman Z-Score of 1.16 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.16
Piotroski F-Score	6